How does severe kidney disease affect a new Drug's levels?
NCT ID NCT06814132
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the drug MK-5684 behaves in the body of men with severe kidney disease or end-stage renal disease compared to healthy men. Twenty-four participants received a single dose, and researchers measured drug levels in the blood over time. The goal is to understand how kidney function affects the drug's processing, which could guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-5684 (oral tablet, with prednisone and fludrocortisone acetate)
What this could lead to
If successful, this study could help doctors determine the right dose of MK-5684 for people with severe kidney problems, making treatment safer and more effective.
What could go wrong
This is a small, early-phase study focused on drug levels, not on treating disease. It may not lead to any new treatment, and results may not apply to women or people with milder kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Orlando Clinical Research Center ( Site 0002)
Orlando, Florida, 32809, United States
-
Research by Design ( Site 0001)
Chicago, Illinois, 60643, United States